Solvent for dilution for BI 3720931 inhaler solution clinical trials

A seamless Phase I/II trial with an initial open-label dose escalation part and a subsequent randomised, double-blind, placebo-controlled expansion part to evaluate the safety, tolerability, and efficacy of a single dose of BI 3720931, an inhaled lentiviral vector gene therapy, in adult people with cystic fibrosis who are ineligible for CFTR modulators (LenticlairTM 1)

This study is testing a new inhaled gene therapy, BI 3720931, for adults with cystic fibrosis who can't use other treatments. It will check if the treatment is safe, how well people tolerate it, and if it improves lung function (FEV1pp).